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Abstract 
 
 
This paper outlines how the goals, practices and 
capability levels for the configuration management (CM) 
process area within a software process improvement (SPI) 
framework have been developed. This framework 
addresses an opportunity to integrate the regulatory issues 
and SPI mechanisms so as to achieve improvements that 
are critical to the development of software for medical 
devices [1].  
Software is becoming an increasingly important aspect 
of medical devices and medical device regulation. Medical 
devices can only be marketed if compliance and approval 
from the appropriate regulatory bodies of the Food and 
Drug Administration (FDA) [2] (US requirement), and the 
European Commission under its Medical Device 
Directives (MDD) [3] (CE marking requirement) is 
achieved. Integrated into the design process of medical 
devices, is the requirement of the production and 
maintenance of a device technical file, incorporating a 
design history file.  Design history illustrates the well 
documented, defined and controlled processes and 
outputs, undertaken in the development of medical devices 
and for our particular consideration with this framework - 
the software components. 
 
1. Introduction 
 
Medical device companies base their software 
development processes on the need to comply with the 
FDA and European MDD regulations. To date, however, 
the primary focus has not been on the software processes 
but rather that ensuring the elements that satisfy the 
regulatory requirements are in place. As part of our 
research we sought the opinions of five medical device 
companies in N.Ireland in relation to the importance of 
having effective software processes in place. Each of the 
five companies expressed a desire to have access to a 
software process improvement framework that would 
incorporate the goals of medical device software for 
meeting regulatory compliance.  
 
2. SPI framework development 
 
The Irish Software Engineering Research Centre 
(ISERC) is currently researching how software processes 
my be improved within the embedded software industry. 
As part of this research ISERC is aiming to develop a 
software development framework for the medical device 
sector that addresses existing regulatory requirements for 
the control of the design, development, maintenance and 
support of software. The approach for delivering the 
software development framework is to establish a model 
(implemented as illustrated in figure 1) that addresses the 
relevant regulations, and integrates those constraints 
within an SPI framework (i.e. Medical Device Software 
Process Improvement-MedeSPI).  
The model will be flexible in that relevant elements of 
the SPI framework may be adopted as required to provide 
the most significant benefit to the business. The intention 
is develop two frameworks, one that is based on 
ISO:15504 [4] and the other on the Capability Maturity 
Model Integration ( ®1CMMI  ).  
For the purpose of this paper, the SPI framework used 
will be that of the Capability Maturity Model Integration 
CMMI® [5] (as this work is at a more advanced stage) 
and the regulations used to extend the CMMI® framework 
will be those of the FDA and the ANSI/AAMI 
SW68:2001 standard (SW68) (Medical device software – 
Software life cycle processes) [6] 
 
 
 
 
 
                                                 
®1 CMMI is registered in the U.S. Patent and Trademark Office by 
Carnegie Mellon University 
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              Test in the medical device industry 
 
Figure 1: Software framework approach  
The MedeSPI framework was initiated by work that 
one of the authors performed whilst performing research 
for the Centre for Software Process Technologies at the 
University of Ulster. This author is now progressing this 
work with the ISERC. The initial research work was 
assisted by the involvement of a steering group with a pilot 
of 5 medical device companies and a notified standards 
body (all based in N.Ireland). However, we now intend 
extending the steering group to include companies in the 
Republic of Ireland.  
The Software Development Method for Medical 
Devices (SDMMD) will be a defined set of software 
process models (in effect a methodology) which when 
utilised will meet the goals of MedeSPI. SDMMD will 
cover the complete lifecycle. The project is divided into 
several stages. 
1. Assess the need for and commitment to the 
creation of SDMMD and MedeSPI; 
2. I
dentify which parts of the CMMI® are required 
to comply with FDA regulation and extend the 
CMMI® with new goals and practices that are 
necessary to achieve FDA compliance (i.e. 
creation of MedeSPI); 
3. Develop process models for meeting the goals of 
MedeSPI (i.e.create SDMMD); 
4. Test SDMMD with Irish medical device 
companies. 
We have completed stage 1 of this work and are 
currently performing  stage 2 activities. In fact stage 2 has 
been performed for the risk management [7] and 
requirements management [8] process areas.  
 
3. MedeSPI Development 
 
SDMMD will provide a software development 
methodology, which addresses the regulatory guidance 
criteria, while introducing best practices that can be 
selected as required.  MedeSPI will provide a means of 
assessing software engineering capability in twelve areas 
that have been defined by the FDA [9,10,11]  as:   
1. Level of Concern;  
2. Software Description;  
3. Device Hazard and Risk Analysis;  
4. Software Requirements Specification; 
5. Architecture Design; 
6. Design Specifications; 
7. Requirements Traceability Analysis; 
8. Development; 
9. Validation; 
10. Verification and Testing; 
11. Revision Level History; 
12. Unresolved Anomalies & Release Version 
Number. 
 
MedeSPI is being developed to promote SPI practices 
into the software development processes of medical device 
companies. This is an attempt to improve the effectiveness 
and efficiency of software processes used by medical 
device companies through investigating the mapping 
between twelve CMMI® process areas and the twelve FDA 
areas listed above. The twelve CMMI® process areas that 
we have deemed appropriate for the medical device 
industry are as follows:  
1. Project Planning; 
2. Project Monitoring & Control; 
3. Supplier Agreement Management; 
4. Risk Management; 
5. Requirements Management; 
6. Requirements Development; 
7. Technical Solution; 
8. Product Integration; 
9. Verification; 
10. Validation; 
11. Configuration Management; 
12. Process and Product Quality Assurance. 
 
The mappings between the FDA regulatory guidelines 
and the CMMI® process areas listed above then produce 
twelve MedeSPI process areas which retain the CMMI® 
process area names listed above. Each of the MedeSPI 
process areas will then be composed of a number of goals 
and practices. Goals and practices may be either generic 
(relating to the entire organisation) or specific (relating to 
the current process area).  MedeSPI investigates what parts 
of the CMMI® process areas are required to satisfy FDA 
regulations, but also investigates the possibility of 
extending the CMMI® process areas with additional goals 
and practices that are outside the remit of CMMI®, but are 
required in order to satisfy FDA regulations (see figure 
2). 
 
Extend the CMMI 
with new goals and 
practices 
CMMI 
 
FDA & 
SW68 
 
 MedeSPI 
SDMMD:  Software Development 
Method for Medical Devices 
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A- CMMI Practices, not mandatory for  FDA. 
B- CMMI Practices that are required for FDA . 
C- Non-CMMI Practices, mandatory for FDA. 
 
Figure 2. Composition of the MedeSPI framework. 
 
The model will help companies to measure their 
organisational capability and to track progression and 
achievements in each of the twelve process areas and 
against process capability levels.  The MedeSPI 
framework has adopted the following capability levels: 
• Level 0 – In other SPI models level 0 indicates that a 
process is not performed. However, this is not the case 
within MedeSPI. Level 0 means that companies 
perform practices that enable them to adhere to 
medical device regulations. Companies must 
demonstrate that a process area satisfies the goals and 
performs the practices required to achieve FDA 
regulatory compliance. This will involve performing 
some practices which the CMMI® views as generic, 
although not to the extent of fulfilling any generic 
goals. 
• Level 1 - Companies must demonstrate that a process 
area satisfies level 0 and the CMMI® capability level 
1 goal of performing the CMMI® base practices. 
• Level 2 – Companies must demonstrate that a process 
area satisfies level 1 and additionally performs 
CMMI® Advanced Practices, as well as the CMMI® 
capability level 2 generic goal of Institutionalising a 
Managed Process. 
• Level 3 - Companies must demonstrate that a process 
area satisfies level 2 and additionally the CMMI® 
Generic Goal to Institutionalise a Defined Process 
(CMMI® Generic Goal 3). 
• Level 4 – Companies must demonstrate that a process 
area satisfies level 3 and additionally the CMMI® 
Generic Goal to Institutionalise a Quantitatively 
Managed Process (CMMI® Generic Goal 4). 
• Level 5 - Companies must demonstrate that a process 
area satisfies level 4 and additionally the CMMI® 
Generic Goal to Institutionalise an Optimising Process 
(CMMI® Generic Goal 5). 
 
Section 4 details a mapping of existing software 
development guidelines for the medical device industry 
against the CMMI  for the CM process area. The FDA 
provides little insight into how CM should be performed 
other than to state that a CM plan should exist and that this 
should be adopted to manage configuration items for 
medical device software. Therefore in order to gain a 
greater understanding of the CM guidelines that medical 
device companies follow in order to achieve regulatory 
compliance we referred to the Medical device software-
Software life cycle processes (SW68) standard. This 
standard was drafted for use in the medical device sector 
based on the lifecycle requirements of ISO/IEC 12207 
[12].  
A 
B C 
 
4. Configuration management (CM) 
 
CM can be defined as “the unique identification, 
controlled storage, change control, and status reporting of 
selected intermediate work products, product components 
and products during the life of a system” [13].  
For many software companies, who report CM 
problems, it is the first major process weakness that they 
are required to address. For example, as the company 
expands, it must fulfil the task of acquiring new customers 
whilst satisfying the demands of existing customers. Often 
these demands include product customisations which 
many young companies, lacking reliable revenue streams, 
do not feel they can ignore. In many situations this results 
in companies having to support multiple code bases and 
product versions with very limited resources. Ultimately, a 
detailed CM process is the only way this problem can be 
solved.   
A study of a small Danish software firm shows how it 
was forced to review the number of products it developed, 
and the amount of work it accepted, because of CM 
difficulties [14]. But CM is equally important in large 
software companies as a case study of Netscape and 
Microsoft’s development practices shows [15]. Therefore, 
in a software company or department without CM to 
control product development, there is no process to assess 
and no basis for measurement [[16].  
To succeed in this area Humphrey [17] proposes that a 
CM plan be developed in conjunction with the 
establishment of a configuration control board to manage 
changes to all of the baseline configuration items and to 
ensure that configuration control procedures are followed.  
There are four main activities to be considered as part 
of any CM strategy: identification, storage, change 
control, & status reporting [13]. 
Identification is concerned with uniquely categorising 
each configuration item and its relations to the outside 
world and other configuration items. A configuration item 
is an object, produced in several versions, which is placed 
under CM. Storage ensures that a configuration item will 
not disappear or be damaged, and can be readily retrieved 
as required. Change Control must properly manage any 
change requests and modifications made to products, and 
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4.1.1.2  Establish a CM System (1.2-1). Establishing a 
CM system involves demonstrating that the sub-practices 
listed in Table 2 are being performed.   
provide traceability for any amendments to configuration 
items. Status reporting provides the information necessary 
to manage a product’s development and maintenance. 
These issues are covered in detail under CMMI’s CM 
process area. 
Table 2, shows the mapping between the SW68 and 
FDA guidelines for each of the sub-practices within 
CMMI®  SP 1.2-1. Therefore, in order to adhere to the 
FDA and SW68  guidelines, only 2 of the 8 activities 
required for CMMI
4.1 CM mapping of FDA & SW68 against the 
CMMI ® SP 1.2-1 (Establishing a CM system) 
are necessary. The main differences are that CMMI® 
requests the usage of multiple control levels of CM, as 
well as archiving and restoration procedures to be in place.  
  
This section illustrates the MedeSPI capability 
structure for the CM process area. In order to achieve this, 
FDA regulations [2,9,10,11] & SW68 guidelines were 
mapped against the goals and practices of the CMMI
 
Table 2: MedeSPI capability levels for 
establishing a CM system 
® CM 
process area. We did not find any additional goals or 
practices (not included in the CMMI® Sub-Practice Level ) that would have to 
be added in order the satisfy the  FDA and SW68 
guidelines.  
 Establish a mechanism to manage multiple 
control levels of CM. 
1 
 Store and retrieve configuration items in the 
CM system. 
0 CM has three specific goals (SG). These are as 
follows: SG1: Establish Baselines, SG2: Track and 
Control Changes & SG3: Establish Integrity. To meet 
each of these goals it is necessary for a number of specific 
practices to be performed.  
 Share and transfer configuration items between 
control levels within the CM system. 
1 
 Store and recover archived versions of 
configuration items. 
1 
  Store, update, and retrieve CM records. 0 
4.1.1 SG1: Establish Baselines. In order to fulfil SG1: 
“Establish Baselines” the following specific practices 
have to be performed: 1.1-1 Identify Configuration Items, 
1.2-1 Establish a CM System; & 1.3-1 Create or Release 
Baselines. 
 Create CM reports from the CM system. 1 
 Preserve the contents of the CM system. 1 
Revise the CM structure as necessary 1 
  
4.1.1.1 Identify Configuration Items (1.1-1). Identifying 
configuration items involves demonstrating that the sub-
practices listed in Table 1 are being performed.  
4.1.1.3 Create or Release Baselines (1.3-1). Creating or 
releasing baselines, involves demonstrating that the sub-
practices listed in Table 3 are being performed.  
Table 1, shows the mapping between the SW68 and 
FDA guidelines for each of the sub-practices within 
CMMI
Table 3, shows the mapping between the SW68 and 
FDA guidelines for each of the sub-practices within 
CMMI
® SP 1.1-1. Therefore, in order to adhere to SW68  
and FDA guidelines only 3 out of the 5 activities required 
for CMMI
® SP 1.3-1. Therefore, in order to adhere to the 
FDA and SW68  guidelines only one of the 4 activities 
required for CMMI
® SP 1.1-1 (Identifying Configuration items) 
are necessary (that is those indicated as level 0 sub-
practices) 
® SP 1.3-1 (Creating or releasing 
baselines) are necessary.  
 
 Table 3: MedeSPI capability levels for creating 
or releasing baselines Table 1: MedeSPI capability levels for 
identifying configuration items 
Sub-Practice Level 
Sub-Practice Level 
Obtain authorisation from the CCB before 
creating or releasing baselines of configuration 
items 
1 
Select the configuration items and the work 
products that compose them based on 
documented criteria. 
0 
Create or release baselines only from 
configuration items in the CM system 
1 
 Assign unique identifiers to configuration 
items. 
0 
Document the set of configuration items that are 
contained in a baseline 
0 
 Specify the important characteristics of each 
configuration item. 
1 
Make the current set of baselines readily available 1 
 Specify when each configuration item is placed 
under CM. 
0  
 
 Identify the owner responsible for each 
configuration item. 
1  
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®4.1.2 SG2 Track and Control Changes.  
4.1.2.1 Track Change Requests (2.1-1). Tracking change 
requests, involves demonstrating that the sub-practices 
listed in Table 4 are being performed.  
Table 4, shows the mapping between the SW68 and 
FDA guidelines for each of the sub-practices within 
CMMI® SP 2.1-1. Therefore, in order to adhere to the 
FDA and SW68  guidelines all of the activities required 
for CMMI® SP 2.1-1 (Tracking change requests) are 
necessary, but not always to the same level of detail. 
 
Table 4: MedeSPI capability levels for tracking 
change requests 
Sub-Practice Level 
 Initiate and record change requests in the change 
request database 
0 
 Analyse the impact of changes and fixes 
proposed in the change requests. 
0 
Review change requests that will be addressed in 
the next baseline with those who will be affected 
by the changes and get their agreement. 
0 
 Track the status of change requests to closure. 0 
 
4.1.2.2 Control Configuration Items (2.2-1). Controlling 
configuration items, involves demonstrating that the sub-
practices listed in Table 5 are being performed.  
Table 5, shows the mapping between the SW68 and 
FDA guidelines for each of the sub-practices within 
CMMI® SP 2.2-1. As the control of configuration items is 
very important in terms of ensuring the integrity of 
medical device software it is therefore no surprise that 4 of 
the 5 activities required for CMMI® SP 2.2-1 (Controlling 
configuration items) are necessary in order to adhere to 
the FDA and SW68  guidelines. 
 
Table 5: MedeSPI capability levels for 
controlling configuration items 
Sub-Practice Level 
Control changes to configuration items 
throughout the life of the product. 
0 
Obtain appropriate authorisation before changed 
configuration items are entered into the CM 
system. 
0 
Check in and check out configuration items from 
the CM system for incorporation of changes in a 
manner that maintains the correctness and 
integrity of the configuration items. 
1 
Perform reviews to ensure that changes have not 
caused unitended effects on the baselines 
0 
Record changes to configuration items and the 
reasons for the changes as appropriate 
0 
 
4.1.3 SG 3 Establish Integrity 
4.1.3.1 Establish CM Records (3.1-1). Establishing CM 
records, involves demonstrating that the sub-practices 
listed in Table 6 are being performed.  
Table 6, shows the mapping between the SW68 and 
FDA guidelines for each of the sub-practices within 
CMMI  SP 3.1-1. The process of establishing CM records 
is very important in terms of providing the traceability 
evidence that is required to meet the regulatory 
requirements associated with medical device software. 
Therefore, it is no surprise that most of the activities (3 out 
of 5 ) required for CMMI® SP 3.1-1 (Establishing CM 
records) are necessary in order to adhere to the FDA and 
SW68  guidelines. 
 
Table 6: MedeSPI capability levels for 
establishing CM records 
Sub-Practice Level 
Record CM actions in sufficient detail so the 
content and status of each configuration item is 
known and previous versions can be recovered. 
0 
Ensure that relevant stakeholders have access to 
and knowledge of the configuration status of the 
configuration items. 
1 
Specify the latest version of the baselines. 1 
Identify the version of the configuration items 
that constitute a particular baseline. 
0 
Describe the differences between successive 
baselines 
1 
Revise the status and history of each 
configuration item as necessary 
0 
 
4.1.3.2 Perform Configuration Audits (3.2-1). 
Performing configuration audits, involves demonstrating 
that the sub-practices listed in Table 7 are being 
performed.  
Table 7, shows the mapping between the SW68 and 
FDA guidelines for each of the sub-practices within 
CMMI® SP 3.2-1. In terms of the mapping of SW68  
process management guidelines against the CMMI® 
guidelines for CM this specific practice in CMMI® has no 
equivalent practice within  the SW68 documentation. The 
SW68 CM documentation does not provide any details on 
the need for auditing the CM processes and activities.   
 
Table 7: MedeSPI capability levels for 
performing configuration audits 
Sub-Practice Level 
Assess the integrity of the baselines 1 
Confirm that the configuration records correctly 
identify the configuration of the configuration 
items.  
1 
Review the structure and integrity of the items in 
the CM system. 
1 
Confirm the completeness and correctness of the 
items in the CM system. 
1 
Confirm compliance with applicable CM 
standards and procedures. 
1 
Track action items from the audit to closure. 1 
 
4.1.4 The Generic goals and practices of CM. The 
CMMI® identifies a number of generic goals and practices. 
At a fundamental maturity or capability level it is only 
necessary to perform the specific base practices. It is 
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® interesting to note that the SW68 guidelines for CM often 
have a counterpart in the CMMI®. For configuraton 
management the generic goals and practices for capability 
level 2 (GG 2: Institutionalise a Managed Process - IMP) 
are: 
• GP 2.1 Establish Policy;  
• GP 2.2 Plan the process;  
• GP 2.3 Provide Resources;  
• GP 2.4 Assign Responsibility;  
• GP 2.5 Train People;  
• GP 2.6 Manage Configurations;  
• GP 2.7 Identify stakeholders;  
• GP 2.8 M&C Process;  
• GP 2.9 Evaluate Adherence; 
• GP 2.10 Review. 
 
Table 8, illustrates what CM goals, practices and sub-
practices have to be performed for each of the MedeSPI 
capability levels.  
 
Table 8: MedeSPI CM generic process area 
components and capability levels 
Goal: GG2: Institutionalise a Managed Process 
Practice Level 
GP 2.1 Establish Policy 0 
GP 2.2 Plan the process 0 
GP 2.3 Provide Resources 0 
GP 2.4 Assign Responsibility 0 
GP 2.5 Train People 0 
GP 2.6 Manage Configurations 2 
GP 2.7 Identify stakeholders 2 
GP 2.8 M&C Process 2 
GP 2.9 Evaluate Adherence 2 
GP 2.10 Review 2 
Goal: GG3: Institutionalise a Defined Process  
Practice Level 
GP 3.1 Establish a defined 
Process 
3 
GP 3.2 Collect Improvement 
Information 
3 
Goal: GG4: Institutionalise a Quantitatively 
Managed Process 
Practice Level 
GP 4.1 Establish Quantitative 
Objectives for the Process 
4
GP 4.2 Stabilise Sub-process 
Performance 
4 
Goal: GG5: Institutionalise an Optimising Process 
Practice Level 
GP 5.1 Ensure Continuous 
Process Improvement  
5 
GP 5.2 Correct Root Causes of 
Problems 
5 
The FDA regulations state that each manufacturer shall 
establish the appropriate responsibility, authority, and 
interrelation of all personnel who manage, perform, and 
assess work affecting quality (this would relate the 
CMMI eneric goal associated with assigning 
responsibility - GP 2.4). It also undertakes to ensure that 
all work is adequately resourced and that staff are trained 
(this sentence relates the CMMI®   generic goals associated 
with providing resources and training - GP 2.3 & GP 2.5). 
Additionally, the  guidelines specify that a company 
should have a policy and a process in place for CM (GP 
2.1 & GP 2.2). However, it should be acknowledged that 
these linkages are made at a very high level as the FDA 
specifies little detail other than a very generic sentence in 
relation to these areas, and no specific guidance as to how 
these activities may be achieved. 
 
5. Conclusions. 
 
With respect to the specific goals and practices of the 
CM process area, it is clear that following FDA and SW68 
guidelines will only, at best, partially meet the goals of this 
CMMI® process area. As might reasonably be expected, 
there is little guidance provided within the FDA 
regulations for the advanced practices of CM. Since failure 
to perform any specific practice implies failure to meet the 
specific goal, with respect to CMMI®, it is clear, that the 
goals of CM cannot be obtained by satisfying FDA and 
SW68 guidelines during software development. But is the 
opposite true, can meeting the CMMI® goals for CM 
successfully meet FDA and SW68 guidelines? Certainly 
for CM, meeting the goals of the process area by 
performing the specific practices would in general more 
than meets the FDA and and SW68 guidelines in this area. 
For CM, the existing CMMI® specification of goals and 
practices can be carried over, with the extension 
mentioned above into the MedeSPI framework. 
This research work will now be extended to develop 
capability models for the the process areas of risk 
management, validation and verification within the 
medical device domain. 
 
6. Acknowledgements. 
 
This research is supported by the Science Foundation 
Ireland funded project, Global Software Development in 
Small to Medium Sized Enterprises (GSD for SMEs) as 
part of the Irish Software Engineering Research Centre - 
ISERC (http://www.iserc.ie). 
 
7. References  
 
[1]. F. Mc Caffery , P. Donnelly, A. Dorling & F.G. Wilkie. 
(Apr 2004) "A Software Process Development, 
Assessment and Improvement Framework for the 
Medical Device Industry", Proceedings of Fourth 
International SPICE Conference on Process Assessment 
and Improvement, Lisbon, Portugal, 28-29 April 2004, 
SPICE User Group (Lisbon, Portugal), ISBN 972-9071-
73-X, Pages 100-109. 
 6/8
[2]. FDA Regulations.  "Code of FederalRegulations 21 
CFR Part 820."  June 1997. 
[3]. European Council, “Council Directive 93/42/EEC 
Concerning Medical Devices”, 14 June 1993. 
[4]. ISO/IEC 15504: Information Technology – Process 
Assessment – Part 5: An exemplar Process Assessment 
Model, ISO/IEC JTC1/SC7, October 2003. 
[5]. Capability Maturity Model® CM Integration  (CMMISM) 
for Software Engineering (CMMI-SW, V1.1, Version 
1.1, August 2002) 
[6]. Medical device software-Software life cycle processes, 
ANSI(American National Standard)/AAMI (Association 
for the Advancement of Medical Instrumentation) 
SW68:2001.  
[7]. F. Mc Caffery, D. McFall, P. Donnelly  , F.G. Wilkie 
“Risk Management Process Improvement for the 
medical device industry”. Proceedings of the 
International Conference on Software Development 
(SWDC-REK-2005) ), University of Iceland, , 27th May 
- 1st June, 2005, in "Software Development", Pages 92-
103 
[8]. F. Mc Caffery, D. McFall, P. Donnelly  , F.G. Wilkie  & 
R. Sterrit. “A Software Process Improvement Lifecycle 
Framework for the Medical Device Industry” , in 
Proceedings of the 12th Annual IEEE International 
Conference on the Engineering of Computer Based 
Systems (ECBS 2005),Greenbelt Marriott Hotel, 
Greenbelt, Maryland, USA (Washington DC metro), 3-8 
April, 2005, Pages 273-280. ISBN 0-7695-2308-0 
[9]. FDA/CDRH Guidance Document. "Guidance for the 
Content of Premarket Submissions for Software 
Contained in Medical Devices."  May 1998. 
[10]. FDA/CDRH Guidance Document.  "Guidance for Off-
the-Shelf Software Use in Medical Devices."    
September 1999 
[11]. FDA/CDRH Guidance Document. "General Principles 
of Software Validation."  June 1997. 
[12]. 1S0/IEC 12207:1995, Information technology – 
Software lifecycle processes 
[13]. A.M. J. Hass, 2003, Configuration Management 
Principles and Practice, Addison Wesley.  
[14]. R. Baskerville and J. Pries-Heje, 1999, ‘Knowledge 
Capability and Maturity in Software Management’, in 
The Data Base for Advances in Information Systems, 
Spring, Vol. 30, No. 2, 26-43. 
[15]. M. A. Cusumano, and D.B. Yoffie, 1999, ‘Software 
Development on Internet Time’, in IEEE Computer, 
Vol. 32, No. 10, Oct., 60-69. 
[16]. M.E. Fayad and M. Laitinen, 1997, ‘Process Assessment 
Considered Wasteful’, in Communications of the ACM, 
Vol. 40, No. 11, 125-128. 
[17]. W. S. Humphrey, 2000, Introduction to the Team 
Software Process, Addison Wesley
                                                 
SM SCAMPI is a service mark of Carnegie Mellon 
University 
 7/8
  8/8
